eFoodSafety Announces Successful Citroxin Lab Tests Against 'Superbug' Eradicating MRSA Strain of Staph

Scottsdale, AZ - (WORLD STOCK WIRE) - November 20, 2007 -- eFoodSafety.com, Inc. (OTCBB: EFSF) announced today that it has conducted tests, which were successful, using a microbial inhibition study to determine if Citroxin would eradicate the MRSA bacteria (methicillin resistant staphylococcus aureus or antibiotic resistant staphylococcus aureus). The microbial inhibition study is commonly used to determine antimicrobial effectiveness of antibiotics against known pathogens in a clinical microbiological setting. Citroxin far exceeded the acceptable level of inhibition against MRSA than demonstrated by standard antibiotics normally used against non-MRSA staphylococcus.

MRSA is a particularly difficult type of staph infection that is causing serious concern for the nation's health care system. MRSA is a sub-group that comprises about 40% of staph bacteria and has become resistant to beta-lactams, antibiotics normally used to treat staph infections. These include methicillin, amoxicillin, and penicillin. An antibiotic known as vancomycin has been utilized as an ace-in-the-hole treatment for these so-called superbugs, but there is now evidence that these bacterial strains are developing a resistance to it also. Although there are other antibiotic resistant bacteria, MRSA is the culprit responsible for most infections. Symptoms of a MRSA infection can range from mild to severe. A mild staph infection might produce swelling, redness, fever, and the need for drainage of pus or other fluids from the site of infection. Symptoms of moderate staph infections may include rash, high fever, shortness of breath, fatigue, muscle aches, and headaches. Staph infections that become severe or occur in people with compromised immunity may cause cellulitis, endocarditis, toxic shock syndrome, blood poisoning, and pneumonia. If left untreated, organ failure or even death can occur.

Staphylococcus aureus (staph) are a common and normally harmless bacteria that live on the skin and in the nasal passages of about 30% of the population. Staph can cause an infection when they enter the skin through a cut or sore or enter the body through a feeding tube or catheter or any other break in the skin.

Normally, MRSA occurs in hospital settings in "dirty areas," such as floors, toilets, waiting rooms, and areas open to hand touch. Proper cleaning is paramount to keeping infections like MRSA at bay, but one study indicated that even when up to 90% of a hospital's wards looked clean, they were in fact only 30-45% microbially clean.

Biobelt Microbiological Labs, whose director Kirk Hartwein, a microbiologist, has over 13 years of experience in doing microbiologic testing for both national and international firms, conducted the tests resulting in the determination that Citroxin far exceeded the acceptable level of inhibition against MRSA than typically demonstrated by standard antibiotics normally used against non-MRSA staphylococcus.

A suspension of MRSA was prepared and distributed evenly into a Petri dish to create a full lawn growth (full coverage of MRSA across the dish). After proper incubation, the Petri dish with MRSA was inoculated with Citroxin. The sample was allowed to incubate for 24 hours and then studied for inhibitory effect. Determination was made based on if Citroxin could inhibit MRSA, and if so how far from the focal point of Citroxin inoculation would this inhibition occur. The inhibitory effect was dramatic. Citroxin exhibited a very strong inhibitory effect, far exceeding what other strong efficacious antibiotics show with inhibition tests for staphylococcus.

Patricia Gruden, President and CEO of eFoodSafety.com, Inc. stated, "All one has to do to understand the importance of today's announcement is turn on the news. MRSA is a particularly difficult type of antibiotic resistant staph infection that is causing serious concern for the nation's health care system. In fact, very recently, there have been cases of MRSA in schools in Florida and in New York. The case in New York resulted in the death of a 12-year old boy. Health officials in New York estimate that there were at least 600 confirmed cases of MRSA infection last year among school children between the ages of 5 to 18. In recent years, MRSA has been occurring in seemingly healthy people who had not been hospitalized. Known as community-based MRSA, these infections have been showing up in athletes who share equipment like towels, and in children at school. We're clearly pleased to now have an objective third party confirmation of Citroxin's effectiveness towards battling one of these new mutations of once easily curable infectious diseases which have built up immunity to common remedies."

Citroxin is an environmentally safe product formulated entirely of food-grade components. In Environmental Protection Agency (EPA) required laboratory tests, Citroxin showed a 100% kill rate for the "big six" bacterial health threats: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, as well as Avian Influenza and Black Mold.

About eFoodSafety.com, Inc.

eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The OraPhyte(TM) product which has been tested and shown to be effective at eradicating nematodes by the U.S. Department of Agriculture is currently at three major universities with outstanding Agricultural Departments undergoing crop-specific research.

The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn(TM)-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn(TM) line.

The Company is also owner of Cinnergen(TM), a clinically-studied, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com) and Cinnechol(TM), a multi-faceted nutritional supplement specifically designed to naturally reduce total cholesterol levels without causing any side effects. The Company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect(TM) anti-acne skin care system.

Please visit the Company's website at: http://www.efoodsafety.com.

Safe Harbor Forward-Looking Statements
Statements contained in this release that are not strictly historical are "forward-looking statements." Such forward-looking statements are sometimes identified by words such as "intends," "anticipates," "believes," "expects" and "hopes." The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.



Patricia Gruden
efoodsafety.com, Inc.
7702 East Doubletree Ranch Road
Suite 300
Scottsdale, AZ 85258
USA

Phone: 415-884-0348
Fax: 480-348-3999


Source: efoodsafety.com, Inc.
Note: The following press release was submitted by: efoodsafety.com, Inc., and World Stock Wire, Inc. is not liable for the contents of this press release.